Healthcare rotation as AI selloff hedge · Thesis · Arbora ↑

As AI and technology stocks sold off sharply on June 5, investors rotated into healthcare names as a defensive alternative, with one article explicitly noting healthcare stocks gaining traction as investors move away from volatile AI and technology names. Amgen received European Commission approval for a new therapy, AbbVie secured EU approval for another drug, and Merck announced detailed results from a Moderna collaboration — a cluster of positive clinical and regulatory catalysts arriving simultaneously. The combination of defensive rotation demand and pipeline execution makes diversified biopharma an attractive hedge against AI valuation compression.

Core thesis

A simultaneous wave of EU regulatory approvals and pipeline catalysts across large-cap biopharma, coinciding with a sharp AI/tech selloff, positions diversified healthcare as a high-conviction defensive rotation trade with both macro and fundamental tailwinds.

Causal chain

AI and technology valuations compress under selling pressure → risk-off sentiment drives institutional and retail capital out of high-multiple growth names → investors seek sectors with lower beta, more predictable cash flows, and near-term fundamental catalysts → healthcare and biopharma absorb rotation inflows, as explicitly evidenced by UnitedHealth and Eli Lilly leading a sector rebound → simultaneously, Amgen, AbbVie, and Merck deliver a cluster of positive regulatory and clinical newsflow (EC approvals for IMDYLLTRA® and AQUIPTA®, plus Merck-Moderna collaboration data) → pipeline execution validates the fundamental case independent of macro sentiment → combined demand from defensive rotation and stock-specific catalysts creates a dual-engine bid for the sector → sector multiple expansion and relative outperformance versus AI/tech names follow. The bear interruption point sits between steps two and three: if the AI selloff proves shallow or reverses quickly, the rotation impulse dissipates before it fully accretes into healthcare prices, leaving the thesis dependent solely on the regulatory catalysts.

Key drivers

  • Defensive rotation demand: The AI/tech selloff on June 5 was sharp enough to prompt explicit sector rotation into healthcare, with UnitedHealth and Eli Lilly named as direct beneficiaries, suggesting institutional-level repositioning rather than retail noise.
  • Regulatory catalyst cluster: Three member tickers — AMGN, ABBV, and MRK — received or announced material regulatory and clinical milestones within days of each other, reducing idiosyncratic risk and reinforcing the sector-wide narrative.
  • EU market access expansion: EC approvals for IMDYLLTRA® (Amgen) and AQUIPTA® (AbbVie) open new revenue streams in a major regulated market, providing tangible near-term commercial upside beyond the US pipeline.
  • Merck-Moderna collaboration data: Detailed results from the Merck-Moderna collaboration add a forward-looking innovation signal, suggesting MRK's pipeline is progressing on multiple fronts simultaneously.
  • Valuation relativity: With AI/tech names under valuation compression, large-cap biopharma with visible earnings and dividend support becomes relatively more attractive on a risk-adjusted basis, drawing capital that would otherwise sit in growth names.
  • Breadth of coverage: The thesis spans five diversified large-cap names (LLY, NVO, AMGN, ABBV, MRK), reducing single-stock concentration risk and making the trade accessible via sector-level positioning.

Risks and counter-case

  • AI/tech reversal: If the June 5 selloff proves transient and AI/tech names recover quickly, the rotation impulse fades and healthcare loses its relative bid, leaving the sector without a macro catalyst.
  • Regulatory approval already priced in: EC approvals for IMDYLLTRA® and AQUIPTA® may have been anticipated by the market; if so, the newsflow represents a "sell the news" event rather than incremental upside.
  • Pipeline execution risk: Positive early-stage or collaboration data (Merck-Moderna) does not guarantee commercial success; late-stage failures or label restrictions could reverse sentiment rapidly.
  • Sector-specific policy headwinds: Large-cap biopharma remains exposed to drug pricing legislation and regulatory scrutiny; any adverse policy development could overwhelm the rotation tailwind.
  • Concentration in GLP-1 names: LLY and NVO carry significant GLP-1 exposure; any clinical safety signal, competitive entrant, or reimbursement setback in that category would disproportionately impact the thesis basket.
  • Correlation breakdown: In a broad risk-off event (rather than a sector rotation), healthcare may not decouple from equities generally, limiting its hedging utility against a deeper market drawdown.
  • Short duration of catalyst window: Regulatory and clinical catalysts are point-in-time events; without a sustained pipeline of upcoming newsflow, the fundamental support for the thesis may erode within weeks.

What to watch

  • Relative sector performance (XLV vs. QQQ): Sustained outperformance of healthcare versus the Nasdaq is the primary confirmation signal that rotation is structural rather than a one-day reaction.
  • AI/tech volatility regime: Monitor whether the June 5 selloff extends or reverses; a continued downtrend in high-multiple tech names is a necessary condition for sustained rotation inflows into healthcare.
  • Commercial uptake guidance for IMDYLLTRA® and AQUIPTA®: Early launch metrics or management commentary on EU market penetration will indicate whether the regulatory approvals translate into revenue acceleration.
  • Merck-Moderna collaboration milestones: Watch for subsequent data readouts, trial enrollment updates, or partnership expansions that would confirm the collaboration is progressing toward commercialization.
  • Institutional fund flow data: Sector fund flow reports (e.g., weekly ETF inflows into XLV, IBB) will confirm whether the rotation is being sustained by institutional reallocation or was a single-session event.
  • Earnings guidance revisions for LLY and NVO: Given their GLP-1 weight in the basket, any upward or downward revision to volume and pricing guidance is a high-impact signal for the thesis.
  • Drug pricing legislative developments: Any movement on Medicare negotiation scope or international reference pricing proposals could rapidly shift the risk/reward calculus for the entire basket.

Sources

  1. UnitedHealth, Eli Lilly Lead Healthcare Rebound as Investors Seek Stability 2026-06-05

    Explicit statement that healthcare stocks gain traction as investors rotate from AI/tech

  2. Amgen Inc. (AMGN) Announces EC’s Grant of Marketing Authorization for IMDYLLTRA® 2026-06-05

    Amgen receives European Commission approval for new therapy, positive pipeline catalyst

  3. AbbVie (ABBV) Announces European Commission’s Approval of AQUIPTA® 2026-06-05

    AbbVie receives European Commission approval for another drug on June 2

  4. Is Merck & Co. (MRK) One of the Best Cheap Stocks to Buy for Beginners? 2026-06-05

    Merck and Moderna announce detailed results from collaboration on June 1

  5. Yahoo Finance 2026-06-05

    Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026

  6. Yahoo Finance 2026-06-05

    AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

  7. Yahoo Finance 2026-06-05

    Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally

  8. Yahoo Finance 2026-06-05

    AGEN Early Access Revenues Signal a New Path Ahead of Approval

  9. Yahoo Finance 2026-06-05

    Is Agenus Stock a Hold Amid Valuation and Funding Risks?

  10. Yahoo Finance 2026-06-05

    AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

  11. Yahoo Finance 2026-06-05

    GLP-1 Sales Forecast Jumps To $150 Billion By 2030

  12. Yahoo Finance 2026-06-05

    Here’s Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade

  13. Yahoo Finance 2026-06-05

    Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations

  14. Yahoo Finance 2026-06-05

    Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year

  15. Yahoo Finance 2026-06-06

    Assessing Whether Amgen (AMGN) Is Slightly Undervalued After Recent Share Price Gains

  16. Yahoo Finance 2026-06-06

    Eli Lilly Broadens Beyond Obesity Drugs With Vaccine And Genetic Bets

  17. Yahoo Finance 2026-06-06

    Assessing Merck (MRK) Valuation After Recent Share Price Momentum And Earnings Growth

  18. Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Sto 2026-06-06

    Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?

  19. Yahoo Finance 2026-06-06

    People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched t

  20. Yahoo Finance 2026-06-06

    Novo Nordisk Eyes Next GLP 1 Wave With Amycretin Trial Results

  21. Yahoo Finance 2026-06-06

    Jim Cramer Says Eli Lilly CEO Is a “Terrific Steward of His Shareholders’ Capital”

  22. Eli Lilly makes surprising retreat from major market 2026-06-06

    Eli Lilly makes surprising retreat from major market

  23. Yahoo Finance 2026-06-06

    Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

  24. Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing 2026-06-06

    Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing

  25. Yahoo Finance 2026-06-06

    Is It Too Late To Consider Eli Lilly (LLY) After Its 48% One-Year Surge?

  26. Yahoo Finance 2026-06-06

    Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

  27. Yahoo Finance 2026-06-06

    AbbVie (ABBV) Valuation Check After New Cancer And Migraine Drug Approvals

  28. Yahoo Finance 2026-06-06

    Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

  29. Yahoo Finance 2026-06-07

    Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets

  30. Yahoo Finance 2026-06-07

    How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases

  31. Yahoo Finance 2026-06-07

    Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

  32. Yahoo Finance 2026-06-07

    Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

  33. Related: Megacap tech AI monetization and valuation divergence 2026-06-07

    Spillover from a related thesis (semantic)

  34. Related: GLP-1 and obesity drug coverage expansion 2026-06-07

    Spillover from a related thesis (shares holding)

  35. Related: Healthcare managed care and aging demographics 2026-06-07

    Spillover from a related thesis (shares holding)

  36. Yahoo Finance 2026-06-07

    AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

  37. Wall Street sees huge upside as Novo Nordisk backs biotech company 2026-06-08

    Wall Street sees huge upside as Novo Nordisk backs biotech company

  38. Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO) 2026-06-08

    Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

  39. Yahoo Finance 2026-06-08

    Eli Lilly Obesity Wins Recast Retatrutide And Foundayo As Cardiometabolic Story

  40. Yahoo Finance 2026-06-08

    Q1 Earnings Review: Branded Pharmaceuticals Stocks Led by Eli Lilly (NYSE:LLY)

  41. Yahoo Finance 2026-06-08

    Big Pharma Stock Eli Lilly Concocts New Buy Zone

  42. Yahoo Finance 2026-06-08

    Zacks Investment Ideas feature highlights: Eli Lilly and Merck

  43. Yahoo Finance 2026-06-08

    Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro

  44. Yahoo Finance 2026-06-08

    Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?

  45. Yahoo Finance 2026-06-08

    Novo Nordisk Explores Wegovy Combination And Wider Semaglutide Benefits As Shares Fall

  46. Yahoo Finance 2026-06-08

    Eli Lilly Shares Rise Pre-Bell After Additional Retatrutide Data Shows Improvements in Obesity-Related Conditions

  47. LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials 2026-06-08

    LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials

  48. Yahoo Finance 2026-06-08

    Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

  49. Yahoo Finance 2026-06-08

    Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics'

  50. Yahoo Finance 2026-06-08

    Eli Lilly's Weight-Loss Pill Clears Its Toughest Hormonal Test Yet

  51. Yahoo Finance 2026-06-08

    Lilly Rises on Retatrutide Data

  52. Yahoo Finance 2026-06-08

    Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

  53. Yahoo Finance 2026-06-08

    Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

  54. Yahoo Finance 2026-06-08

    Novo Drops 3.2% As CEO Eyes Longevity And Aesthetics

  55. Yahoo Finance 2026-06-08

    Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other

  56. Yahoo Finance 2026-06-09

    Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating

  57. Yahoo Finance 2026-06-09

    Why Eli Lilly (LLY) Stock Is Up Today

  58. Yahoo Finance 2026-06-09

    Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?

  59. Yahoo Finance 2026-06-09

    The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains

  60. Yahoo Finance 2026-06-09

    Pentagon Accuses Alibaba, Baidu of Aiding China’s Military

  61. Yahoo Finance 2026-06-09

    AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project

  62. Yahoo Finance 2026-06-09

    Global Chromatography Market to Reach $21.50 Billion by 2031, Fueled by Biologic Purification Needs

  63. Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure 2026-06-09

    Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

  64. Yahoo Finance 2026-06-09

    Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?

  65. Yahoo Finance 2026-06-09

    Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

  66. Yahoo Finance 2026-06-09

    EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton

  67. Novo Nordisk puts AI at the centre of its clinical strategy 2026-06-09

    Novo Nordisk puts AI at the centre of its clinical strategy

  68. Yahoo Finance 2026-06-09

    Novo Wegovy Pill Tops 3M Prescriptions

  69. Yahoo Finance 2026-06-09

    Sector Update: Healthcare Stocks Rise Late Afternoon

  70. Yahoo Finance 2026-06-09

    Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study

  71. Yahoo Finance 2026-06-09

    Eli Lilly Expands Alzheimer’s Pipeline With AlzeCure Deal And Valuation Upside

  72. Yahoo Finance 2026-06-09

    Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus

  73. Yahoo Finance 2026-06-09

    Eli Lilly (LLY) Reports Positive Foundayo Weight Loss Data for Menopausal Women

  74. LLY’s EBGLYSS Gets FDA Nod For Every-8-Weeks Dosing, Cutting Treatment To Six Injections Per Year 2026-06-09

    LLY’s EBGLYSS Gets FDA Nod For Every-8-Weeks Dosing, Cutting Treatment To Six Injections Per Year

  75. Yahoo Finance 2026-06-09

    FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

  76. Yahoo Finance 2026-06-09

    Assessing Novo Nordisk (CPSE:NOVO B) Valuation As Share Price Weakness Follows A Tough Year

  77. Yahoo Finance 2026-06-09

    Lilly Makes a New Alzheimer's Pipeline Move

  78. Yahoo Finance 2026-06-09

    What's Driving Amneal's 2026 Growth Outlook?

  79. Yahoo Finance 2026-06-10

    Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?

  80. Yahoo Finance 2026-06-10

    Planisware unveils latest AI innovations at its annual Exchange26 EMEA conference

  81. Yahoo Finance 2026-06-10

    Merck Expands EU Traceability Push And Targets Bundibugyo Ebola Response

  82. Yahoo Finance 2026-06-10

    European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

  83. Yahoo Finance 2026-06-10

    Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care

  84. Yahoo Finance 2026-06-10

    Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable

  85. Yahoo Finance 2026-06-10

    Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case

  86. Yahoo Finance 2026-06-10

    Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics

  87. Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement 2026-06-10

    Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement

  88. Yahoo Finance 2026-06-10

    FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story

  89. Yahoo Finance 2026-06-10

    Top Research Reports for Merck, Southern Company & Lumentum

  90. Yahoo Finance 2026-06-10

    Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)

  91. Yahoo Finance 2026-06-10

    Coastal Financial And 2 Additional Stocks Estimated To Be Priced Below Intrinsic Value

  92. Yahoo Finance 2026-06-10

    ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push

  93. Yahoo Finance 2026-06-10

    Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

  94. Yahoo Finance 2026-06-10

    Can Gilead Sciences HIV Franchise Drive Long-Term Growth?

  95. Yahoo Finance 2026-06-10

    ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth

  96. AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine 2026-06-10

    AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

  97. Yahoo Finance 2026-06-11

    Novo Nordisk hit by cyber incident, probes data breach

  98. Yahoo Finance 2026-06-11

    Novo Nordisk A/S: IT Security incident at Novo Nordisk

  99. Yahoo Finance 2026-06-11

    Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

  100. Yahoo Finance 2026-06-11

    Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?

  101. Yahoo Finance 2026-06-11

    Is PAHC Undervalued at 10x Earnings vs Peers?

  102. Yahoo Finance 2026-06-11

    Novo Nordisk (NVO): Top 10 Large Cap Value Stocks to Buy Now

  103. Yahoo Finance 2026-06-11

    Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now

  104. Yahoo Finance 2026-06-11

    Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?

  105. Yahoo Finance 2026-06-11

    Sector Update: Healthcare Stocks Higher Late Afternoon

  106. Yahoo Finance 2026-06-11

    Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it

  107. NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News 2026-06-11

    NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News

  108. Yahoo Finance 2026-06-11

    Novo Nordisk Cybersecurity Breach Puts Data Controls And Investor Confidence In Focus

  109. Yahoo Finance 2026-06-11

    Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know

  110. Yahoo Finance 2026-06-12

    Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies

  111. Yahoo Finance 2026-06-12

    Oral Wegovy FDA Win Reframes Novo Nordisk Growth And Longevity Story

  112. Yahoo Finance 2026-06-12

    AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Result

  113. Yahoo Finance 2026-06-12

    Merck TARGAN Deal Highlights Poultry Tech Push And Undervalued Share Price

  114. UK gives Wegovy GLP-1 pill first European approval 2026-06-12

    UK gives Wegovy GLP-1 pill first European approval

  115. Yahoo Finance 2026-06-12

    Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

  116. Yahoo Finance 2026-06-12

    Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline — Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment.

  117. Yahoo Finance 2026-06-12

    Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight

  118. Yahoo Finance 2026-06-12

    Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach — NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.

  119. Yahoo Finance 2026-06-12

    PAHC Stock: What's Driving Phibro's Animal Health Growth — Phibro Animal Health unit drove 74% of fiscal 2025 revenue, fueled by MFA, vaccines and global expansion, helping offset pressure in other businesses.

  120. Yahoo Finance 2026-06-12

    Merck (MRK) Stock After 53% One-Year Gain Is DCF Signaling Further Upside Potential — For investors considering whether Merck at around US$120.76 still offers value or whether most of the upside is already reflected in the price, this article walks through the key checks investors often rely on.

  121. Yahoo Finance 2026-06-12

    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell R

  122. Yahoo Finance 2026-06-12

    Sector Update: Healthcare Stocks Softer Late Afternoon

  123. Yahoo Finance 2026-06-12

    Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth

  124. Yahoo Finance 2026-06-12

    Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up. — Eli Lilly is committed to innovation and reinvests 20%-25% of its sales back into developing new treatments.

  125. Yahoo Finance 2026-06-12

    Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance

  126. Yahoo Finance 2026-06-12

    AbbVie (ABBV) Rises Higher Than Market: Key Facts — AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.

  127. Novo Nordisk comeback stirs as Wegovy pill wins UK approval 2026-06-12

    Novo Nordisk comeback stirs as Wegovy pill wins UK approval

  128. Abridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion 2026-06-12

    Abridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion

  129. Yahoo Finance 2026-06-12

    2 Cash-Producing Stocks on Our Buy List and 1 That Underwhelm

  130. Yahoo Finance 2026-06-13

    Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

  131. Yahoo Finance 2026-06-13

    Jim Cramer Wasn’t Selling Eli Lilly (LLY)

  132. Yahoo Finance 2026-06-13

    Novo Nordisk (NVO) Reports Positive Phase 3 Reimagine Trial Results

  133. Yahoo Finance 2026-06-13

    Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now

  134. Yahoo Finance 2026-06-13

    Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? — With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks to buy according to hedge funds. Meanwhile, analysts see 9.20% upside for the stock.